IQI - Incannex thrilled with positive pre-IND meeting for arthritis treatment
(NewsDirect)
Incannex HealthcareLtd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackleytells Proactive the company has completed a constructivepre-Investigational New Drug (IND) application meeting with the USFood and Drug Administration (FDA) for its IHL-675A proprietary drugtargeted at the treatment of rheumatoid arthritis (RA).
IHL-675A is acombination of cannabidiol (CBD) and hydroxychloroquine sulphatedesigned to address inflammatory disorders including RA. A successfulIND application is a requirement to conduct trials in the US andensures trials are designed to meet data requirements for future FDAapprovals.
Feedback received from the FDA in the pre-IND meeting is highlyvaluable for the continued development of IHL-675A for treatment ofrheumatoid arthritis,” Bleackley said.
“The agency’s responses covered multipleaspects of our development strategy that will be incorporated into ourclinical trial designs and research plans.
“We look forward to continuing to work with the FDA to ensurethat the IHL-675A development program generates high-quality data thataddresses the requirements set forth by the agency.”
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.